特发性肺纤维化
医学
病因学
疾病
肺
病理生理学
格尔德
重症监护医学
间质性肺病
内科学
病理
回流
作者
Joseph M. Parker,Michael R. Kramer,Lynne A. Murray
出处
期刊:Inflammation and Allergy - Drug Targets
[Bentham Science]
日期:2013-04-01
卷期号:12 (2): 109-123
标识
DOI:10.2174/1871528111312020005
摘要
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, irreversible, and usually fatal interstitial lung disease of unknown cause [1, 2]. The aetiology of IPF is unknown, although identified risk factors for IPF include cigarette smoking, environmental exposures, microbial agents, age, male gender and gastroesophageal reflux disease (GERD). Genetic factors may also play a role in the aetiology of IPF as familial cases of IPF are described in approximately 5% of patients with IPF [2]. Nothing has shown significant anti-fibrotic activity in IPF patients and due to this high unmet medical need, numerous therapeutics are currently under clinical investigation. In this review, we shall focus on recombinant protein based approaches for the treatment of IPF, with a particular focus on pathophysiology of lung fibrosis using the bleomycin mouse model. Keywords: Bleomycin, epithelium, fibroblast, lung fibrosis, macrophage.
科研通智能强力驱动
Strongly Powered by AbleSci AI